Your ability to engage patients dictates success and failure in your clinical trials. While steps have been taken to improve our patient involvement, we still struggle with recruitment issues around volume and diversity as well as active engagement in redesigning innovative trials and rolling out DCTs.
But tools and strategies do exist to alleviate our patient engagement ailments. By partnering with patient advocacy groups, building inclusion criteria into protocol designs and using AI and data analytics to unlock actionable patient insights, we can shorten our drug development timelines and get our medicines to patients in need.
Join us for an exclusive Reuters Events webinar to hear industry experts discuss how to:
• Leverage patient insights to accelerate drug development and boost personalization, resulting in faster access to medicines, enhanced adherence rates, and heighted trust in your company
• Bridge the gap between patient engagement and drug development through the power of data analytics and AI, facilitating faster research, predictive, accurate trials, and streamlined regulatory approval
• Expand the diversity of your participant populations through redesigned protocols, expanded DCTs and innovative trial designs that are rooted in patient centricity
Kate Pavlik, EXECUTIVE DIRECTOR, FUNCTIONAL SERVICE PARTNERSHIP SOLUTIONS CLINICAL RESEARCH, PPD
Barbara Valastro, PH.D., HEAD PATIENT SCIENCE, ASTRAZENECA
, MSC, EUPATI ALUMNA, PATIENT EXPERT, PATIENT LEAD, EUPATI